AZD6140

DRUG6 trials

Sponsors

AstraZeneca

Conditions

Blood Flow SpeedCoronary Artery DiseaseCoronary Flow VelocityGoutHealthyPharmacokineticsRenal Impairment

Phase 1

AZD6140 Oral Contraceptive Interaction Study

CompletedNCT00685906

AstraZenecaHealthy

Start: 2008-04-30End: 2008-10-31Target: 24Updated: 2010-12-02

An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers

CompletedNCT00721448

AstraZenecaPharmacokinetics

Start: 2008-06-30End: 2008-08-31Target: 24Updated: 2010-12-03

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

CompletedNCT00733265

AstraZenecaRenal Impairment

Start: 2007-02-28End: 2008-09-30Target: 24Updated: 2010-12-03

Uric Acid Study in Healthy Male Volunteers

CompletedNCT00738842

AstraZenecaCoronary Artery Disease, Gout

Start: 2008-05-31End: 2008-07-31Updated: 2010-12-03

Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

CompletedNCT01226602

AstraZenecaBlood Flow Speed, Coronary Flow Velocity

Start: 2010-12-31End: 2011-04-30Updated: 2012-02-13

Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers

CompletedNCT01588626

AstraZenecaHealthy

Start: 2012-05-31End: 2012-06-30Updated: 2012-07-13

Related Papers

Ticagrelor: analysis of clinical trial registries

Figshare2014-01-01

Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.

2013-01-09140 citations

Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.

2012-02-0144 citations